B
B Fisher
Researcher at Allegheny University of the Health Sciences
Publications - 25
Citations - 5863
B Fisher is an academic researcher from Allegheny University of the Health Sciences. The author has contributed to research in topics: Breast cancer & Mastectomy. The author has an hindex of 22, co-authored 25 publications receiving 5743 citations.
Papers
More filters
Journal ArticleDOI
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.
TL;DR: The findings continue to indicate that lumpectomy followed by breast irradiation is appropriate therapy for women with either negative or positive axillary nodes and breast tumors 4 cm or less in diameter.
Journal ArticleDOI
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
B Fisher,James J. Dignam,Norman Wolmark,D. Lawrence Wickerham,Edwin R. Fisher,Eleftherios P. Mamounas,Roy E. Smith,Mirsada Begovic,Nikolay V. Dimitrov,Richard G. Margolese,Carl G Kardinal,Maureen T. Kavanah,Louis Fehrenbacher,Robert H Oishi +13 more
TL;DR: The combination of lumpectomy, radiation therapy, and tamoxifen was effective in the prevention of invasive cancer and the risk of ipsilateral-breast cancer was lower in the tamoxIFen group even when sample margins contained tumour and when DCIS was associated with comedonecrosis.
Journal ArticleDOI
Significance of ipsilateral breast tumour recurrence after lumpectomy.
B Fisher,Stewart J. Anderson,Edwin R. Fisher,Carol K. Redmond,D. L. Wickerham,Norman Wolmark,Eleftherios P. Mamounas,Melvin Deutsch,Richard G. Margolese +8 more
TL;DR: 9-year follow-up data from B-06 are used here to address the issue of ipsilateral breast tumour recurrence (IBTR) and the development of distant disease, a question with important clinical and biological implications.
Journal ArticleDOI
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.
B Fisher,Stewart J. Anderson,D L Wickerham,Arthur DeCillis,Nikolay V. Dimitrov,Eleftherios P. Mamounas,Norman Wolmark,R Pugh,James N. Atkins,Frederick J. Meyers,Neil Abramson,J Wolter,R Bornstein,L Levy,Edward H. Romond,V Caggiano,M Grimaldi,P Jochimsen,Peter J. Deckers +18 more
TL;DR: It was concluded that, outside of a clinical trial, dose-intensification of cyclophosphamide in an AC combination represents inappropriate therapy for women with primary breast cancer.
Journal ArticleDOI
Treatment of Primary Breast Cancer with Chemotherapy and Tamoxifen
B Fisher,Carol K. Redmond,Ann M. Brown,Norman Wolmark,James L. Wittliff,Edwin R. Fisher,D Plotkin,Bowman D,Sachs S,J Wolter,Robert Frelick,Desser R,LiCalzi N,Geggie P,Campbell T,Elias Eg,David Prager,Koontz P,Volk H,Nikolay V. Dimitrov,Gardner B,Harvey J. Lerner,Shibata H +22 more
TL;DR: This adjuvant chemotherapy is not indicated in patients less than orequal to 49 years old whose tumor receptor levels are below 10 fmol; there is a suggestion of benefit in patients greater than or equal to 50 years oldwhose levels are low.